TOP > 外国特許検索 > Anticancer agent

Anticancer agent

外国特許コード F170009053
整理番号 AF12-12US2
掲載日 2017年4月26日
出願国 アメリカ合衆国
出願番号 201615166647
公報番号 20160340441
出願日 平成28年5月27日(2016.5.27)
公報発行日 平成28年11月24日(2016.11.24)
国際出願番号 JP2013055927
国際公開番号 WO2013133253
国際出願日 平成25年3月5日(2013.3.5)
国際公開日 平成25年9月12日(2013.9.12)
優先権データ
  • 特願2012-052334 (2012.3.8) JP
  • 2013US-14383118 (2013.3.5) US
  • 2013WO-JP55927 (2013.3.5) WO
発明の名称 (英語) Anticancer agent
発明の概要(英語) (US20160340441)
According to the present invention, an anticancer agent is provided that has as an active ingredient thereof a human antibody light chain that demonstrates cytotoxicity against cancer cells and particularly lung cancer cells.
The anticancer agent of the present invention primarily comprises: a human antibody κ-type light chain in the form of a dimer in which the variable region is composed of a polypeptide represented by the amino acid sequence of SEQ ID NO: 1, 9 or 13 or an amino acid sequence in which one or a plurality of amino acids have been added, deleted or substituted in these amino acid sequences; or, a human antibody κ-type light chain in the form of a monomer in which the variable region is composed of a polypeptide represented by the amino acid sequence of SEQ ID NO: 19 or an amino acid sequence in which one or a plurality of amino acids have been added, deleted or substituted in the amino acid sequence.
特許請求の範囲(英語) [claim1]

1-2. (canceled)
[claim2]
3. A method of eradicating cancer cells or suppressing or inhibiting a proliferation of the cancer cells, comprising: administering a therapeutically effective amount of an anticancer composition to an object requiring an administration, the anticancer composition comprising:
(5) a human antibody kappa -type light chain in the form of a monomer in which a variable region is composed of a polypeptide of
an amino acid sequence of SEQ ID NO: 19,
an amino acid sequence in which one or a plurality of the amino acids in regions other than the CDRs in the amino acid sequence have been substituted, added or deleted, or
an amino acid sequence having homology of 95% or more with the amino acid sequence and having the same CDRs of the amino acid sequence,
wherein the CDRs in the amino acid sequence of SEQ ID NO: 19 are the first 24 to 39 amino acid residues, the first 55 to 61 amino acid residues, and the first 94 to 101 amino acid residues.
[claim3]
4. A method of eradicating cancer cells or suppressing or inhibiting a proliferation of the cancer cells according to claim 3, wherein the human antibody kappa -type light chain of (5) above is a human antibody kappa -type light chain in the form of a monomer composed of a polypeptide of
an amino acid sequence in which cysteine at position 219 has been deleted or substituted by an amino acid other than cysteine in the amino acid sequence of SEQ ID NO: 20,
an amino acid sequence in which one or a plurality of the amino acids in regions other than the CDRs in the amino acid sequence have been substituted, added or deleted, or
an amino acid sequence having homology of 95% or more with the amino acid sequence and having the same CDRs of the amino acid sequence,
wherein the CDRs in the amino acid sequence of SEQ ID NO: 20 are the first 24 to 39 amino acid residues, the first 55 to 61 amino acid residues, and the first 94 to 101 amino acid residues.
[claim4]
5. A method of eradicating cancer cells or suppressing or inhibiting a proliferation of the cancer cells according to claim 3, wherein the object requiring the administration develops lung cancer.
[claim5]
6. A method of eradicating cancer cells or suppressing or inhibiting a proliferation of the cancer cells according to claim 3, wherein the anticancer composition demonstrates a cytotoxicity against cancer cells which are present on a cell surface.
[claim6]
7. A method of eradicating cancer cells or suppressing or inhibiting a proliferation of the cancer cells according to claim 3, comprising: administrating the anticancer composition in a form which enables the anticancer composition to be delivered to pneumocytes from a nose or bronchi.
[claim7]
8. A method of eradicating cancer cells or suppressing or inhibiting a proliferation of the cancer cells according to claim 3, wherein protein contained in the anticancer composition is administered at a dose of 0.01 mg/kg to 30 mg/kg of body weight.
  • 発明者/出願人(英語)
  • UDA TAIZO
  • HIFUMI EMI
  • JAPAN SCIENCE AND TECHNOLOGY AGENCY
国際特許分類(IPC)
参考情報 (研究プロジェクト等) CREST Establishment of Innovative Manufacturing Technology Based on Nanoscience AREA
ライセンスをご希望の方、特許の内容に興味を持たれた方は、問合せボタンを押してください。

PAGE TOP

close
close
close
close
close
close